Aikening ® (albuvirtide) Granted Approval by the Food and Drug Administration in China for Use as An Intravenous Bolus Injection Improves Convenience and Compliance

  • 2022-11-04  14:59:38

Frontier Biotechnologies announced in October 2022, it has obtained approval from the Food and Drug Administration in China for Aikening® (albuvirtide) for use as an intravenous bolus injection, as an additional route of administration.

The current route of administration for Aikening® is via intravenous infusion approximately over 45 minutes. And with the new approval for administering it via a bolus injection intravenously between thirty seconds to three minutes, the shortened administration time offers significant convenience and improved compliance for both healthcare providers and people living with HIV.

The new drug delivery is potentially promising for people to remain on Aikening® therapy post hospitalisation in outpatient settings, thus maximising the full treatment benefits of Aikening®. Aikening® in combination with other antiretroviral treatment is effective for both major and drug-resistant viral strains and is recommended to be administered once a week.

Develop Innovative Therapies to Better Human Lives